Results 171 to 180 of about 3,613,281 (296)
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Data-driven synthetic microbes for sustainable future. [PDF]
NPJ Syst Biol ApplMariam I +4 more
europepmc +1 more source
Notes on the biology of the tea-tussock-moth, Euproctis pseudoconspersa Strand
, 1956 Junko Hosoya
openalex +1 more source
Reports on the Marine Biology of the Sudanese Red Sea.-X. Hydroida collected by Mr. C. Crossland from October 1904 to May 1905. [PDF]
, 1908 Laura Roscoe Thornely
openalex +1 more source
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?
Molecular Oncology, EarlyView.Chen‐xi Li, Zhong‐cheng Gong
wiley +1 more source
Neural activity patterns stabilize during wakefulness and conscious experience. [PDF]
PLoS Biolvan Gaal S.
europepmc +1 more source